Navidea Biopharmaceuticals (NAVB) 10-Q 13 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 06, 2020
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000810509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		26,687,198
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 3,722,852	$ 1,047,159
Stock subscriptions and other receivables	820,211	901,339
Prepaid expenses and other	249,888	967,285
Total current assets	4,792,951	2,915,783
Property and equipment	838,714	1,207,537
Less accumulated depreciation and amortization	704,411	1,177,327
Property and equipment, net	134,303	30,210
Right-of-use lease assets	458,280	404,594
Less accumulated amortization	178,003	122,906
Right-of-use lease assets, net	280,277	281,688
License agreements, patents and trademarks	680,750	478,672
Less accumulated amortization	119,638	93,259
License agreements, patents and trademarks, net	561,112	385,413
Other assets	227,192	537,812
Total assets	5,995,835	4,150,906
Current liabilities:
Accounts payable	1,115,871	1,112,069
Accrued liabilities and other	2,246,634	2,150,974
Notes payable	366,000	305,955
Lease liabilities, current	285,913	250,553
Total current liabilities	4,014,418	3,819,551
Lease liabilities	380,236	512,344
Deferred revenue	700,000	700,000
Total liabilities	5,094,654	5,031,895
Commitments and contingencies (Note 10)
Stockholders’ equity (deficit):
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding as of September 30, 2020 and December 31, 2019, respectively
Series D preferred stock subscribed; $.001 par value, 148,500 and 0 shares subscribed as of September 30, 2020 and December 31, 2019, respectively	149
Series D preferred stock subscriptions receivable	(14,150,000)
Common stock; $.001 par value; 300,000,000 shares authorized; 26,373,908 and 19,234,960 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	217,370	210,232
Common stock subscribed; $.001 par value, 1,000,000 and 902,162 shares subscribed as of September 30, 2020 and December 31, 2019, respectively	1,000	902
Common stock subscriptions receivable	(5,000,000)
Additional paid-in capital	375,154,360	345,847,676
Accumulated deficit	(356,053,002)	(347,671,102)
Total Navidea stockholders' equity (deficit)	169,877	(1,612,292)
Noncontrolling interest	731,304	731,303
Total stockholders’ equity (deficit)	901,181	(880,989)
Total liabilities and stockholders’ equity (deficit)	$ 5,995,835	$ 4,150,906

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock subscriptions, subscribed (in shares)	148,500	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	26,373,908	19,234,960
Common stock, shares outstanding (in shares)	26,373,908	19,234,960
Common stock subscription, shares authorized (in shares)	1,000,000	902,162

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Revenue from contract with customer		$ 7,000	$ 5,000	$ 31,000	$ 35,000
Grant and other revenue		261,616	231,916	664,848	514,589
Total revenue		268,389	236,811	695,762	538,527
Cost of revenue		82	195	1,048	6,559
Gross profit		268,307	236,616	694,714	531,968
Operating expenses:
Research and development		1,377,998	1,801,558	3,659,046	3,612,783
Selling, general and administrative		1,788,934	1,519,496	4,946,279	5,109,612
Total operating expenses		3,166,932	3,321,054	8,605,325	8,722,395
Loss from operations	[1]	(2,898,625)	(3,084,438)	(7,910,611)	(8,190,427)
Other income (expense):
Interest (expense) income, net		(149)	11,858	12,822	23,336
Other, net		(564)	(1,524)	(777)	(5,880)
Total other (expense) income, net	[2]	(713)	10,334	12,045	17,456
Loss before income taxes		(2,899,338)	(3,074,104)	(7,898,566)	(8,172,971)
Provision for income taxes					(707)
Loss from continuing operations		(2,899,338)	(3,074,104)	(7,898,566)	(8,173,678)
Loss from discontinued operations, net of tax effect					(2,665)
Net loss		(2,899,338)	(3,074,104)	(7,898,566)	(8,176,343)
Loss (income) attributable to noncontrolling interest			2	(1)	16
Deemed dividend on Series C and Series D Preferred Stock beneficial conversion features		(405,555)		(483,333)
Net loss attributable to common stockholders		$ (3,304,893)	$ (3,074,102)	$ (8,381,900)	$ (8,176,327)
Loss per common share (basic and diluted):
Continuing operations (in dollars per share)		$ (0.13)	$ (0.17)	$ (0.37)	$ (0.62)
Attributable to common stockholders (in dollars per share)		$ (0.13)	$ (0.17)	$ (0.37)	$ (0.62)
Weighted average shares outstanding (in shares)		25,843,732	18,044,406	22,946,201	13,082,393
Royalty [Member]
Revenue:
Revenue from contract with customer		$ 2,047	$ 4,895	$ 26,188	$ 13,985
License [Member]
Revenue:
Revenue from contract with customer		$ 4,726		$ 4,726	$ 9,953
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Net loss	$ (2,899,338)	$ (2,325,619)	$ (2,673,608)	$ (3,074,104)	$ (2,673,179)	$ (2,429,061)	$ (7,898,566)	$ (8,176,343)
Unrealized (loss) gain on available-for-sale securities				(188)	(40)	958		730
Comprehensive loss	$ (2,899,338)	$ (2,325,619)	$ (2,673,608)	$ (3,074,292)	$ (2,673,219)	$ (2,428,103)	$ (7,898,566)	$ (8,175,613)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]Private Placement [Member]	Common Stock [Member]Registered Direct Offering [Member]	Common Stock [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Common Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]Series D Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]Registered Direct Offering [Member]	Additional Paid-in Capital [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]Series D Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]Private Placement [Member]	Retained Earnings [Member]Registered Direct Offering [Member]	Retained Earnings [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Retained Earnings [Member]Series C Preferred Stock [Member]	Retained Earnings [Member]Series D Preferred Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]Private Placement [Member]	AOCI Attributable to Parent [Member]Registered Direct Offering [Member]	AOCI Attributable to Parent [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	AOCI Attributable to Parent [Member]Series C Preferred Stock [Member]	AOCI Attributable to Parent [Member]Series D Preferred Stock [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]Private Placement [Member]	Noncontrolling Interest [Member]Registered Direct Offering [Member]	Noncontrolling Interest [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Noncontrolling Interest [Member]Series C Preferred Stock [Member]	Noncontrolling Interest [Member]Series D Preferred Stock [Member]	Noncontrolling Interest [Member]	Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Registered Direct Offering [Member]	Preferred Stock [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock Subscription [Member]Private Placement [Member]	Preferred Stock Subscription [Member]Registered Direct Offering [Member]	Preferred Stock Subscription [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Preferred Stock Subscription [Member]Series C Preferred Stock [Member]	Preferred Stock Subscription [Member]Series D Preferred Stock [Member]	Preferred Stock Subscription [Member]	Preferred Stock Subscriptions Receivable [Member]Private Placement [Member]	Preferred Stock Subscriptions Receivable [Member]Registered Direct Offering [Member]	Preferred Stock Subscriptions Receivable [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Preferred Stock Subscriptions Receivable [Member]Series C Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]Series D Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]	Common Stock Subscription [Member]Private Placement [Member]	Common Stock Subscription [Member]Registered Direct Offering [Member]	Common Stock Subscription [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Common Stock Subscription [Member]Series C Preferred Stock [Member]	Common Stock Subscription [Member]Series D Preferred Stock [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member]Private Placement [Member]	Common Stock Subscriptions Receivable [Member]Registered Direct Offering [Member]	Common Stock Subscriptions Receivable [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Common Stock Subscriptions Receivable [Member]Series C Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member]Series D Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member]	Private Placement [Member]	Registered Direct Offering [Member]	Conversion from Series C Preferred Stock To Common Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018						10,019,535
Balance at Dec. 31, 2018						$ 200,391						$ 338,265,383						$ (336,722,905)						$ (730)						$ 668,321																																				$ 2,410,460
Stock Issued						$ 357						49,643																																																						50,000
Stock Issued (in shares)						17,857
Stock compensation expense												61,978																																																						61,978
Net (loss) income																		(2,429,049)												(12)																																				(2,429,061)
Total comprehensive income (loss)																																																																		(2,428,103)
Issued restricted stock						$ 300																																																												300
Issued restricted stock (in shares)						15,000
Issued restricted stock						$ 300																																																												300
Unrealized (loss) gain on available-for-sale securities																								958																																										958
Balance (in shares) at Mar. 31, 2019						10,052,392
Balance at Mar. 31, 2019						$ 201,048						338,377,004						(339,151,954)						228						668,309																																				94,635
Balance (in shares) at Dec. 31, 2018						10,019,535
Balance at Dec. 31, 2018						$ 200,391						338,265,383						(336,722,905)						(730)						668,321																																				$ 2,410,460
Issued stock in payment of employee bonuses (in shares)																																																																		8,128
Net (loss) income																																																																		$ (8,176,343)
Total comprehensive income (loss)																																																																		(8,175,613)
Unrealized (loss) gain on available-for-sale securities																																																																		730
Balance (in shares) at Sep. 30, 2019						18,059,406
Balance at Sep. 30, 2019						$ 209,056						343,929,129						(344,899,232)												668,304																																				(92,743)
Balance (in shares) at Dec. 31, 2018						10,019,535
Balance at Dec. 31, 2018						$ 200,391						338,265,383						(336,722,905)						(730)						668,321																																				$ 2,410,460
Issued stock in payment of employee bonuses (in shares)																																																																		8,128
Balance (in shares) at Sep. 30, 2020						26,373,908																																				148,500												1,000,000
Balance at Sep. 30, 2020						$ 217,370						375,154,360						(356,053,002)												731,304												$ 149						$ (14,150,000)						$ 1,000						$ (5,000,000)						$ 901,181
Balance (in shares) at Mar. 31, 2019						10,052,392
Balance at Mar. 31, 2019						$ 201,048						338,377,004						(339,151,954)						228						668,309																																				94,635
Stock Issued						$ 8,000						5,158,441																																																						5,166,441
Stock Issued (in shares)						8,000,000
Stock compensation expense												66,159																																																						66,159
Net (loss) income																		(2,673,176)												(3)																																				(2,673,179)
Total comprehensive income (loss)																																																																		(2,673,219)
Issued stock to 401(k) plan (in shares)						8,128
Issued stock to 401(k) plan						$ 8						19,580																																																						19,588
Unrealized (loss) gain on available-for-sale securities																								(40)																																										(40)
Rounding adjustments related to reverse stock split (in shares)						(1,114)
Rounding adjustments related to reverse stock split												(3,385)																																																						(3,385)
Issued stock to 401(k) plan (in shares)						8,128
Value of warrants issued in connection with public offering												261,288																																																						841,559
Balance (in shares) at Jun. 30, 2019						18,059,406
Balance at Jun. 30, 2019						$ 209,056						343,879,087						(341,825,130)						188						668,306																																				2,931,507
Stock compensation expense												50,042																																																						50,042
Net (loss) income																		(3,074,102)												(2)																																				(3,074,104)
Total comprehensive income (loss)																																																																		(3,074,292)
Unrealized (loss) gain on available-for-sale securities																								(188)																																										(188)
Balance (in shares) at Sep. 30, 2019						18,059,406
Balance at Sep. 30, 2019						$ 209,056						343,929,129						(344,899,232)												668,304																																				(92,743)
Balance (in shares) at Dec. 31, 2019						19,234,960																																																902,162
Balance at Dec. 31, 2019						$ 210,232						345,847,676						(347,671,102)												731,303																								$ 902												(880,989)
Issued stock in payment of services (in shares)						3,810
Issued stock in payment of services						$ 4						4,797																																																						4,801
Issued stock in payment of employee bonuses (in shares)						53,315
Issued stock in payment of employee bonuses						$ 53						64,458																																																						64,511
Stock Issued	$ 902	$ 1,000						$ 699,000																																									$ (902)													$ 700,000
Stock Issued (in shares)	902,162	1,000,001																																															(902,162)
Stock subscribed							2,015,126	549,353																																									$ 2,374	$ 647					(912,500)						1,105,000	550,000
Stock subscribed (in shares)																																																	2,373,529	647,058
Stock compensation expense												39,246																																																						39,246
Net (loss) income																		(2,673,610)												2																																				(2,673,608)
Total comprehensive income (loss)																																																																		(2,673,608)
Balance (in shares) at Mar. 31, 2020						21,194,248																																																3,020,587
Balance at Mar. 31, 2020						$ 212,191						349,219,656						(350,344,712)												731,305																								$ 3,021						(912,500)						(1,091,039)
Balance (in shares) at Dec. 31, 2019						19,234,960																																																902,162
Balance at Dec. 31, 2019						$ 210,232						345,847,676						(347,671,102)												731,303																								$ 902												$ (880,989)
Issued stock in payment of employee bonuses (in shares)																																																																		32,651
Net (loss) income																																																																		$ (7,898,566)
Total comprehensive income (loss)																																																																		$ (7,898,566)
Issued stock to 401(k) plan (in shares)																																																																		94,159
Issued stock to 401(k) plan																																																																		$ 172,000
Unrealized (loss) gain on available-for-sale securities
Issued stock to 401(k) plan (in shares)																																																																		94,159
Balance (in shares) at Sep. 30, 2020						26,373,908																																				148,500												1,000,000
Balance at Sep. 30, 2020						$ 217,370						375,154,360						(356,053,002)												731,304												$ 149						(14,150,000)						$ 1,000						(5,000,000)						$ 901,181
Balance (in shares) at Mar. 31, 2020						21,194,248																																																3,020,587
Balance at Mar. 31, 2020						$ 212,191						349,219,656						(350,344,712)												731,305																								$ 3,021						(912,500)						(1,091,039)
Issued stock in payment of employee bonuses (in shares)						40,844
Issued stock in payment of employee bonuses						$ 41
Stock Issued	$ 1,912	$ 647							$ 699,930																								$ 70																$ (1,912)	$ (647)					520,030						520,030		$ 700,000
Stock Issued (in shares)	1,911,800	647,058																															70,000																(1,911,800)	(647,058)
Stock subscribed																																																							392,470						392,470
Stock compensation expense												34,588																																																						34,588
Net (loss) income																		(2,325,618)												(1)																																				(2,325,619)
Total comprehensive income (loss)																																																																		(2,325,619)
Issued restricted stock (in shares)						10,000
Issued restricted stock						$ 10																																																												10
Issued stock to 401(k) plan (in shares)						32,651
Issued stock to 401(k) plan						$ 33						39,801																																																						39,834
Issued stock upon exercise of warrants (in shares)						300,595
Issued stock upon exercise of warrants						$ 300						(300)
Deemed dividend on Series C Preferred Stock												77,778						(77,778)
Issued stock upon conversion of Series C Preferred Stock (in shares)						410,765																														(70,000)
Issued stock upon conversion of Series C Preferred Stock						$ 411						(341)																								$ (70)
Issued restricted stock						$ 10																																																												10
Issued stock to 401(k) plan (in shares)						32,651
Balance (in shares) at Jun. 30, 2020						24,547,961																																																461,729
Balance at Jun. 30, 2020						$ 215,545						350,178,082						(352,748,108)												731,304																								$ 462												(1,622,715)
Issued stock in payment of services (in shares)						20,000
Issued stock in payment of services						$ 20						65,380																																																						65,400
Stock Issued	$ 462									$ 3,462,828	$ 132,089																							$ 350	$ 2														$ (462)															$ 3,463,178	$ 132,091
Stock Issued (in shares)	461,729																																	350,000	1,500														(461,729)
Stock subscribed							$ 4,999,000				14,849,851																														$ 149						(14,150,000)		$ 1,000						$ (5,000,000)										700,000
Stock subscribed (in shares)																																									148,500								1,000,000
Stock compensation expense												62,515																																																						62,515
Net (loss) income																		(2,899,338)																																																(2,899,338)
Total comprehensive income (loss)																																																																		(2,899,338)
Issued restricted stock		$ 50																																																												50
Deemed dividend on Series C Preferred Stock										388,889	16,667					(388,889)	(16,667)
Issued stock upon conversion of Series C Preferred Stock (in shares)				1,014,311	56,497																													(350,000)	(1,500)
Issued stock upon conversion of Series C Preferred Stock				$ 1,014	$ 56					(664)	$ (54)																							$ (350)	$ (2)
Issued stock in payment of Series C Preferred Stock fees (in shares)				14,205		209,205
Issued stock in payment of Series C Preferred Stock fees				$ 14						$ (14)
Issued stock pursuant to Jubilant MOU						$ 209						999,791																																																						1,000,000
Issued restricted stock (in shares)		50,000
Issued restricted stock		$ 50																																																												$ 50
Unrealized (loss) gain on available-for-sale securities
Balance (in shares) at Sep. 30, 2020						26,373,908																																				148,500												1,000,000
Balance at Sep. 30, 2020						$ 217,370						$ 375,154,360						$ (356,053,002)												$ 731,304												$ 149						$ (14,150,000)						$ 1,000						$ (5,000,000)						$ 901,181

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)	3 Months Ended
	Jun. 30, 2019USD ($)
Stock issuance cost	$ 841,559

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	1 Months Ended		3 Months Ended				9 Months Ended		12 Months Ended	21 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 30, 2020
Cash flows from operating activities:
Net (loss) income			$ (2,899,338)	$ (2,673,608)	$ (3,074,104)	$ (2,429,061)	$ (7,898,566)	$ (8,176,343)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization							51,501	107,794
(Gain) loss on disposal and abandonment of assets							(1,042)	1,672
Stock compensation expense							136,349	178,179
Value of stock issued in payment of employee bonuses							171,522
Value of stock issued in payment of services							70,201
Value of stock issued to 401(k) plan for employer matching contribution							39,834	19,588		$ 20,000
Changes in operating assets and liabilities:
Stock subscriptions and other receivables							781,128	(124,665)
Prepaid expenses, right-of-use lease assets, and other assets							1,029,427	753,034
Accounts payable							3,802	414,250
Accrued, lease and other liabilities							8,269	216,180
Deferred revenue							(9,355)	(11,024)
Net cash used in operating activities							(5,616,930)	(6,621,335)
Cash flows from investing activities:
Proceeds from sales of available-for-sale securities								400,000
Maturities of available-for-sale securities								400,000
(Payments for purchases) proceeds from disposal of equipment							(129,216)	28,382
Proceeds from sale of equipment							1,042
Patent and trademark costs							(202,078)
Net cash (used in) provided by investing activities							(330,252)	828,382
Cash flows from financing activities:
Proceeds from issuance of preferred stock							4,350,000
Proceeds from issuance of common stock	$ 812,000	$ 1,900,000					4,417,560	6,046,915	$ 1,100,000
Proceeds from note payable							366,000
Principal payments on notes payable							(305,955)	(316,074)
Net cash provided by financing activities							8,622,875	5,158,570
Net increase (decrease) in cash and cash equivalents							2,675,693	(634,383)
Cash and cash equivalents, beginning of period	$ 1,047,159			$ 1,047,159		$ 3,475,881	1,047,159	3,475,881	3,475,881	3,475,881
Cash and cash equivalents, end of period		$ 1,047,159	$ 3,722,852		$ 2,841,498		3,722,852	2,841,498	$ 1,047,159	$ 3,722,852
Preferred Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs							(54,730)
Common Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs							$ (150,000)	$ (572,271)

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: September 30, 2020 three nine September 30, 2020 2019 September 30, 2020 not December 31, 2019, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. In March 2020, 19 19 19 may not 19. 19 February 2020 2 second third 2020, 19 19 not b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents , stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: September 30, 2020 December 31, 2019 September 30, 2020 December 31, 2019, $366,000 $306,000, 8. c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. d. Leases: 2018. 12 not 9. e. Series C and Series D Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of “Redeemable Preferred Stocks not not not 11. f . Recent ly Adopted Accounting Standards : August 2018, No. 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 820. 2018 13 December 15, 2019. 2018 13 not g . Recently Issued Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 : Simplifying the Accounting for Income Taxes 2019 12 2019 12 740 2019 12 December 15, 2020, not 2019 12 In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the Company's Annual Report on Form 10 $1.9 10. In addition, the Company is engaged in ongoing litigation with our former President and Chief Executive Officer, Dr. Michael Goldberg. See Notes 6 10. The Company has also been engaged in ongoing litigation with Capital Royalty Partners II L.P. (“CRG”) and pursuing recovery of approximately $4.3 November 27, 2019, $4.3 April 9, 2018 ( 10. In December 2019, 2.1 $1.9 $1.1 2019. $812,000 January 2020. 11. In February 2020, two 4.0 $3.4 $3.4 first three 2020. 11. On May 6, 2020, 420,000 $4.2 $4.2 second third 2020. 11. On August 9, 2020, Tc99m $1.0 The MOU outlines certain terms that are expected to be included in the ELDA, including: ● Jubilant to provide Navidea with an additional $19.0 NAV3 32 2b NAV3 33 3 ● Jubilant will pay license fees and sales-based royalties to Navidea based on revenue generated from the sale of TRA in the licensed territory. ● Jubilant will serve as the exclusive commercial and distribution partner for TRA in the United States, Canada, Mexico, and Latin America. Jubilant will be responsible for all commercialization efforts within the licensed territory. The execution of the ELDA is subject to certain conditions, including negotiation of a definitive agreement in mutually acceptable form and Jubilant's completion of its due diligence. See Note 11. On August 30, 2020, $25.0 $0.001 11. On August 31, 2020, 150,000 $15.0 one 5,147,000 11 16. Navidea intends to use the net proceeds from these transactions to fund its research and development programs, including continued advancement of its two 2b 3 Tc99m The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020. 7 May 18, 2020, $366,000 100% During the ongoing COVID- 19 not 19. February 2020 second third 2020, 19 The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The February 2020 $7.6 August 2020 may $60.0 $20.0 twelve 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3 . Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 not May 11, 2020, Tc99m The Company also has an agreement in place to provide Meilleur Technologies, Inc., (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 90 Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract's transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company's contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no The sublicense of NAV4694 No. 606, Revenue from Contracts with Customers 606” 606 Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three September 30, 2020 2019, $7,000 $5,000, nine September 30, 2020 2019, $31,000 $35,000, three nine September 30, 2020 2019, not The following table disaggregates the Company's revenue from contracts with customers for the three nine September 30, 2020 2019. Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Royalty revenue: Tc99m tilmanocept - Europe $ 2,047 $ 4,895 $ 26,188 $ 13,985 License revenue: Tc99m tilmanocept - Europe $ 4,726 $ — $ 4,726 $ — NAV4694 — — — 9,953 Total license revenue $ 4,726 $ — $ 4,726 $ 9,953 Other revenue: Additional stability studies $ — $ — $ — $ 11,024 The following economic factors affect the nature, amount, timing and uncertainty of the Company's revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not Through September 30, 2020, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the three nine September 30, 2020 2019. Three Months Ended September 30, Nine Months Ended September 30, 20 20 201 9 20 20 201 9 Total deferred revenue, beginning of period $ 860,000 $ 1,195,000 $ 700,000 $ 711,024 Revenue deferred related to sublicense — — 160,000 495,000 Refund of deferred revenue related to sublicense (160,000 ) (495,000 ) (160,000 ) (495,000 ) Revenue recognized from satisfaction of performance obligations — — — (11,024 ) Total deferred revenue, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 The Company had trade receivables of approximately $0 September 30, 2020 December 31, 2019. In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. ASC 606 not 606. 606 not On May 11, 2020 ( March 5, 2015 ( Tc99m Pursuant to the Termination Agreement, the parties agreed that neither owed the other any payments due under the License Agreement as of the Termination Date and that, among other things, SpePharm will no six may ninety

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	4 . Stock-Based Compensation For the three September 30, 2020 2019, $63,000 $50,000, nine September 30, 2020 2019, $136,000 $178,000, not three nine September 30, 2020 2019. A summary of the status of our stock options as of September 30, 2020, nine Nine Months Ended September 30 , 20 20 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 238,470 $ 17.38 7.2 $ — Granted 295,000 2.29 Exercised — — Canceled and Forfeited (3,000 ) 1.06 Expired (500 ) 30.80 Outstanding at end of period 529,970 $ 9.06 8.1 $ 314,880 Exercisable at end of period 114,870 $ 25.20 5.3 $ — A summary of the status of our unvested restricted stock as of September 30, 2020, nine Nine Months Ended September 30 , 20 20 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 15,000 $ 2.75 Granted 60,000 2.90 Vested (15,000 ) 2.75 Forfeited — — Unvested at end of period 60,000 $ 2.90 As of September 30, 2020, $332,000 1.6

Note 5 - Loss Per Share

Note 5 - Loss Per Share	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	5 . Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the nine September 30, 2020 2019 1,106,744 1,490,531 The Company's unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 60,000 15,000 nine September 30, 2020 2019,

Note 6 - Investment in Macropha

Note 6 - Investment in Macrophage Therapeutics, Inc.	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	6 . Investment in Macrophage Therapeutics, Inc. In August 2018, one February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg's claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Y. Michael Rice from MT's board of directors, to invalidate all actions taken by the MT board of directors on or after November 29, 2018 ( In addition, the District Court found Navidea's breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 27, 2020, July 9, 2020, 1 2 3 4 On January 31, 2020, April 1, 2020, On August 24, 2020, not third November 13, 2020. not The fact discovery deadline in the New York Action was set to expire in September 2020, 60 Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 December 1 December 3, 2020. Derivative Action Involving Dr. Goldberg On July 26, 2019, November 20, 2019, April 3, 2020, not 2 10.

Note 7 - Accounts Payable, Accr

Note 7 - Accounts Payable, Accrued Liabilities and Other	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7 . Accounts Payable , Accrued Liabilities and Other Accounts payable as of September 30, 2020 December 31, 2019 $ 65,000 September 30, 2020 December 31, 2019 $676,000 $925,000, 401

Note 8 - Notes Payable

Note 8 - Notes Payable	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	8 . Notes Payable IPFS Corporation In November 2018, $393,000 5.1%. ten $40,000, August 2019. Interest expense related to the IPFS note payable totaled $1,000 $6,000 three nine September 30, 2019, First Insurance Funding In November 2019, $349,000 5.0%. eight $44,000, July 2020. Interest expense related to the FIF note payable totaled $0 $5,000 three nine September 30, 2020, $0 $306,000 September 30, 2020 December 31, 2019, Payroll Protection Program The CARES Act was enacted on March 27, 2020. 7 May 18, 2020, $366,000. 1% eight twenty-four 100% not ten May 12, 2021. May 1, 2022. Summary During the three September 30, 2020 2019, $0 $1,000, nine September 30, 2020 2019, $5,000 $6,000,

Note 9 - Leases

Note 9 - Leases	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	9. Leases We currently lease approximately 5,000 4995 $3,000. June 2023. We also leased approximately 2,000 560 $3,000. March 31, 2019 not In addition, we currently lease approximately 25,000 5600 $27,000 2020. October 2022 five not June 2017, $39,000 October 2022. We also currently lease a vehicle at a monthly payment of approximately $300, September 2021, $100, October 2024. Total operating lease expense was $49,000 $54,000 three September 30, 2020 2019, $151,000 $176,000 nine September 30, 2020 2019, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating leases as of September 30, 2020. Maturity of Lease Liabilities Operating Lease Payments 2020 (remaining) $ 92,711 2021 344,552 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 749,428 Less imputed interest 83,279 Present value of operating lease liabilities $ 666,149 Balance Sheet Classification Current lease liabilities $ 285,913 Noncurrent lease liabilities 380,236 Total operating lease liabilities $ 666,149 Other Information Weighted-average remaining lease term for operating leases (in years) 2.1 Weighted-average discount rate for operating leases 10.9 % Cash paid for amounts included in the present value of operating lease liabilities was $246,000 $249,000 nine September 30, 2020 2019,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 0 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies not CRG Litigation As disclosed in the Company's Annual Report on Form 10 December 2017, $66.0 $66.0 $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On April 9, 2018, $7.1 414 $4.1 $59.0 The Company has also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio related to Navidea's claims that the Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the Lenders in connection with the Global Settlement Agreement reached in 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. November 27, 2019, $66.0 $4.3 April 9, 2018, 414 no December 5, 2019, 10th March 27, 2020, September 23, 2020. first 2021. CRG filed another lawsuit in the Texas Court in April 2018. not $7.1 414 August 28, 2020. not 2. Platinum Li tigation In November 2017, $1.9 March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, September 5, 2019. November 25, 2019, not April 28, 2020 19 not June 4, 2020. September 2, 2020, September 23, 2020 not 2. Goldberg Agreement and Litigation In August 2018, one 1,175,000 1,175,000 18 5% November 2018, 925,000 250,000 On February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg's claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Y. Michael Rice from MT's board of directors, to invalidate all actions taken by the MT board of directors on or after November 29, 2018 ( In addition, the District Court found Navidea's breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 27, 2020, July 9, 2020, 1 2 3 4 On January 31, 2020, April 1, 2020, On August 24, 2020, not third November 13, 2020. not The fact discovery deadline in the New York Action was set to expire in September 2020, 60 Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 December 1 December 3, 2020. Derivative Action Involving Dr. Goldberg On July 26, 2019, November 20, 2019, April 3, 2020, not 2 6. NYSE American Continued Listing Standards On August 14, 2018, not not 1003 $6.0 five 1003 The Company regained compliance with the minimum trading price standard following a one twenty April 26, 2019. On February 14, 2020, $6.0 1003 19 $170,000 September 30, 2020. Even if an issuer has a stockholders' deficit, the NYSE American will not 1 $50,000,000; $50,000,000 two three 2 1,100,000 $15,000,000 400 September 30, 2020, $71.2 not may

Note 11 - Equity

Note 11 - Equity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 1 . Equity In December 2019, 2.1 $1.9 $1.1 2019. $812,000 January 2020. $812,000 December 31, 2019. In February 2020, two 4.0 $3.4 $3.4 4,020,588 first three 2020. On May 6, 2020, 420,000 $4.2 one November 6, 2020, 10% not 19.99% not $4.2 420,000 second third 2020. $467,000 420,000 nine September 30, 2020. 1 420,000 1,425,076 second third 2020. On August 9, 2020, Tc99m 209,205 $1.0 2. On August 30, 2020, $25.0 forty-five 45 1,000,000 $5.00 no ninety 90 $5.00 five 713 no $5.75 not ninety 90 not $25.0 ninety 90 no 4.99% $25,000 $5.0 September 30, 2020. September 30, 2020, not $25,000 2. On August 31, 2020, 150,000 $15.0 one nine 10% may not 19.99% not 2 16. In the event of the liquidation or dissolution of the Company, after payment of the debts and other liabilities of the Company, the holders of Series D Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company and before any payment may x Of the $15.0 $150,000 1,500 third 2020. $17,000 1,500 three September 30, 2020. 1 1,500 56,497 third 2020. $700,000 7,000 October 1, 2020 10 7,000 313,290 October 1, 2020 10 $700,000 $14.2 September 30, 2020. Navidea intends to use the net proceeds from these transactions to fund its research and development programs, including continued advancement of its two 2b 3 Tc99m 2. During the nine September 30, 2020, 94,159 $172,000 2019 During the nine September 30, 2020 2019, 32,651 8,128 401 $40,000 $20,000,

Note 12 - Stock Warrants

Note 12 - Stock Warrants	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	1 2 . Stock Warrants In May 2020, 411,000 300,595 As of September 30, 2020, 991,874 $0.20 $49.80 $18.37 one 14.9

Note 13 - Income Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 3 . Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not September 30, 2020 December 31, 2019, In assessing the realizability of DTAs, management considers whether it is more likely than not not not not September 30, 2020, The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. 2018, 2019 2020. may 2018 2020, 50% 2018, 2019 2020 2021. $621,000 December 31, 2019, 50% 50% December 31, 2019. March 27, 2020. 100% 2018 $621,000 second 2020. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no September 30, 2020 December 31, 2019 not twelve September 30, 2020, 2016 2019 As of September 30, 2020, $142.2 $20.1 $8.8

Note 14 - Segments

Note 14 - Segments	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 4 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two Tc99m NAV4694 April 2018), The information in the following tables is derived directly from each reportable segment's financial reporting. T hree Months Ended September 30 , 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,047 $ — $ — $ 2,047 License revenue 4,726 — — 4,726 Grant and other revenue 106,729 154,887 — 261,616 Total revenue 113,502 154,887 — 268,389 Cost of revenue 82 — — 82 Research and development expenses 1,251,383 126,615 — 1,377,998 Selling, general and administrative expenses, excluding depreciation and amortization (1) — — 1,773,532 1,773,532 Depreciation and amortization (2) 4,027 — 11,375 15,402 (Loss) income from operations (3) (1,268,605 ) 28,272 (1,784,907 ) (2,898,625 ) Other expense (4) — — (713 ) (713 ) Net (loss) income (1,141,990 ) 28,272 (1,785,620 ) (2,899,338 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — — 120,810 T hree Months Ended September 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 4,895 $ — $ — $ 4,895 Grant and other revenue 77,049 154,867 — 231,916 Total revenue 81,944 154,867 — 236,811 Cost of revenue 195 — — 195 Research and development expenses 1,678,423 123,135 — 1,801,558 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 1,052 1,484,155 1,485,207 Depreciation and amortization (2) — — 34,289 34,289 (Loss) income from operations (3) (1,596,674 ) 30,680 (1,518,444 ) (3,084,438 ) Other income (4) — — 10,334 10,334 Income tax (expense) benefit (72 ) 16 55 — Net (loss) income (1,596,746 ) 30,696 (1,508,055 ) (3,074,104 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606 Nine Months Ended September 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 26,188 $ — $ — $ 26,188 License revenue 4,726 — — 4,726 Grant and other revenue 381,103 283,745 — 664,848 Total revenue 412,017 283,745 — 695,762 Cost of revenue 1,048 — — 1,048 Research and development expenses 3,402,160 256,886 — 3,659,046 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 4,895,328 4,894,778 Depreciation and amortization (2) 4,027 — 47,474 51,501 (Loss) income from operations (3) (2,995,218 ) 27,409 (4,942,802 ) (7,910,611 ) Other income (4) — — 12,045 12,045 Net (loss) income (2,995,218 ) 27,409 (4,930,757 ) (7,898,566 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — 8,406 129,216 Nine Months Ended September 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 13,985 $ — $ — $ 13,985 License revenue 9,953 — — 9,953 Grant and other revenue 309,670 204,919 — 514,589 Total revenue 333,608 204,919 — 538,527 Cost of revenue 6,559 — — 6,559 Research and development expenses 3,194,468 418,315 — 3,612,783 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 15,828 4,985,990 5,001,818 Depreciation and amortization (2) — — 107,794 107,794 Loss from operations (3) (2,867,419 ) (229,224 ) (5,093,784 ) (8,190,427 ) Other income (4) — — 17,456 17,456 Provision for income tax (248 ) (20 ) (439 ) (707 ) Net loss from continuing operations (2,867,667 ) (229,244 ) (5,076,767 ) (8,173,678 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (2,870,332 ) (229,244 ) (5,076,767 ) (8,176,343 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 Depreciation and amortization are reflected in selling, general and administrative expenses ( $15,402 $34,289 three September 30, 2020 2019, $51,501 $107,794 nine September 30, 2020 2019, ( 3 Loss from operations does not ( 4 Amounts consist primarily of interest income and interest expense, which are not

Note 15 - Supplemental Disclosu

Note 15 - Supplemental Disclosure for Statements of Cash Flows	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	1 5 . Supplemental Disclosure for Statements of Cash Flows During the nine September 30, 2020 2019, $5,000 $6,000, nine September 30, 2020, 94,159 $172,000 2019 nine September 30, 2020 2019, 32,651 8,128 401 $40,000 $20,000, nine September 30, 2020, 411,000 300,595 nine September 30, 2020, $467,000 420,000 420,000 1,425,076 nine September 30, 2020, $17,000 1,500 1,500 56,497

Note 16 - Subsequent Events

Note 16 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	1 6 . Subsequent Events The Company has evaluated events and transactions subsequent to September 30, 2020 10 Preferred Stock: August 31, 2020, 150,000 $15.0 $150,000 1,500 third 2020. 1,500 56,497 third 2020. $700,000 7,000 October 1, 2020 10 7,000 313,290 October 1, 2020 10 $700,000 $14.2 September 30, 2020. 2 11.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: September 30, 2020 three nine September 30, 2020 2019 September 30, 2020 not December 31, 2019, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. In March 2020, 19 19 19 may not 19. 19 February 2020 2 second third 2020, 19 19 not
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents , stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: September 30, 2020 December 31, 2019 September 30, 2020 December 31, 2019, $366,000 $306,000, 8.
Revenue [Policy Text Block]	c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
Lessee, Leases [Policy Text Block]	d. Leases: 2018. 12 not 9.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	e. Series C and Series D Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of “Redeemable Preferred Stocks not not not 11.
New Accounting Pronouncements, Policy [Policy Text Block]	f . Recent ly Adopted Accounting Standards : August 2018, No. 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 820. 2018 13 December 15, 2019. 2018 13 not g . Recently Issued Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 : Simplifying the Accounting for Income Taxes 2019 12 2019 12 740 2019 12 December 15, 2020, not 2019 12 In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Royalty revenue: Tc99m tilmanocept - Europe $ 2,047 $ 4,895 $ 26,188 $ 13,985 License revenue: Tc99m tilmanocept - Europe $ 4,726 $ — $ 4,726 $ — NAV4694 — — — 9,953 Total license revenue $ 4,726 $ — $ 4,726 $ 9,953 Other revenue: Additional stability studies $ — $ — $ — $ 11,024
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 20 20 201 9 20 20 201 9 Total deferred revenue, beginning of period $ 860,000 $ 1,195,000 $ 700,000 $ 711,024 Revenue deferred related to sublicense — — 160,000 495,000 Refund of deferred revenue related to sublicense (160,000 ) (495,000 ) (160,000 ) (495,000 ) Revenue recognized from satisfaction of performance obligations — — — (11,024 ) Total deferred revenue, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30 , 20 20 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 238,470 $ 17.38 7.2 $ — Granted 295,000 2.29 Exercised — — Canceled and Forfeited (3,000 ) 1.06 Expired (500 ) 30.80 Outstanding at end of period 529,970 $ 9.06 8.1 $ 314,880 Exercisable at end of period 114,870 $ 25.20 5.3 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nine Months Ended September 30 , 20 20 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 15,000 $ 2.75 Granted 60,000 2.90 Vested (15,000 ) 2.75 Forfeited — — Unvested at end of period 60,000 $ 2.90

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2020 (remaining) $ 92,711 2021 344,552 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 749,428 Less imputed interest 83,279 Present value of operating lease liabilities $ 666,149
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 285,913 Noncurrent lease liabilities 380,236 Total operating lease liabilities $ 666,149
Lease, Cost [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (in years) 2.1 Weighted-average discount rate for operating leases 10.9 %

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	T hree Months Ended September 30 , 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,047 $ — $ — $ 2,047 License revenue 4,726 — — 4,726 Grant and other revenue 106,729 154,887 — 261,616 Total revenue 113,502 154,887 — 268,389 Cost of revenue 82 — — 82 Research and development expenses 1,251,383 126,615 — 1,377,998 Selling, general and administrative expenses, excluding depreciation and amortization (1) — — 1,773,532 1,773,532 Depreciation and amortization (2) 4,027 — 11,375 15,402 (Loss) income from operations (3) (1,268,605 ) 28,272 (1,784,907 ) (2,898,625 ) Other expense (4) — — (713 ) (713 ) Net (loss) income (1,141,990 ) 28,272 (1,785,620 ) (2,899,338 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — — 120,810 T hree Months Ended September 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 4,895 $ — $ — $ 4,895 Grant and other revenue 77,049 154,867 — 231,916 Total revenue 81,944 154,867 — 236,811 Cost of revenue 195 — — 195 Research and development expenses 1,678,423 123,135 — 1,801,558 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 1,052 1,484,155 1,485,207 Depreciation and amortization (2) — — 34,289 34,289 (Loss) income from operations (3) (1,596,674 ) 30,680 (1,518,444 ) (3,084,438 ) Other income (4) — — 10,334 10,334 Income tax (expense) benefit (72 ) 16 55 — Net (loss) income (1,596,746 ) 30,696 (1,508,055 ) (3,074,104 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606 Nine Months Ended September 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 26,188 $ — $ — $ 26,188 License revenue 4,726 — — 4,726 Grant and other revenue 381,103 283,745 — 664,848 Total revenue 412,017 283,745 — 695,762 Cost of revenue 1,048 — — 1,048 Research and development expenses 3,402,160 256,886 — 3,659,046 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 4,895,328 4,894,778 Depreciation and amortization (2) 4,027 — 47,474 51,501 (Loss) income from operations (3) (2,995,218 ) 27,409 (4,942,802 ) (7,910,611 ) Other income (4) — — 12,045 12,045 Net (loss) income (2,995,218 ) 27,409 (4,930,757 ) (7,898,566 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — 8,406 129,216 Nine Months Ended September 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 13,985 $ — $ — $ 13,985 License revenue 9,953 — — 9,953 Grant and other revenue 309,670 204,919 — 514,589 Total revenue 333,608 204,919 — 538,527 Cost of revenue 6,559 — — 6,559 Research and development expenses 3,194,468 418,315 — 3,612,783 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 15,828 4,985,990 5,001,818 Depreciation and amortization (2) — — 107,794 107,794 Loss from operations (3) (2,867,419 ) (229,224 ) (5,093,784 ) (8,190,427 ) Other income (4) — — 17,456 17,456 Provision for income tax (248 ) (20 ) (439 ) (707 ) Net loss from continuing operations (2,867,667 ) (229,244 ) (5,076,767 ) (8,173,678 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (2,870,332 ) (229,244 ) (5,076,767 ) (8,176,343 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Notes Payable, Fair Value Disclosure	$ 366,000	$ 306,000

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Jun. 02, 2021	Nov. 05, 2020	Aug. 31, 2020	Aug. 09, 2020	May 18, 2020	May 06, 2020	Nov. 27, 2019	Aug. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Nov. 30, 2017	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Aug. 30, 2020
Stock Issued During Period, Shares, New Issues (in shares)											2,100,000
Proceeds from Issuance of Common Stock										$ 812,000	$ 1,900,000							$ 4,417,560	$ 6,046,915	$ 1,100,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable													$ 5,000,000					5,000,000
Stock Issued During Period, Value, New Issues																$ 5,166,441	$ 50,000
Proceeds from Issuance of Preferred Stock and Preference Stock																		$ 4,350,000
Common Stock, Par or Stated Value Per Share (in dollars per share)											$ 0.001		$ 0.001					$ 0.001		$ 0.001
Proceeds from Notes Payable, Total																		$ 366,000
Increase in Additional Working Capital								$ 20,000,000	$ 7,600,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total					$ 366,000
Forecast [Member]
Increase in Additional Working Capital	$ 60,000,000
Private Placement [Member]
Stock Issued During Period, Value, New Issues														$ 520,030
Series C Preferred Stock [Member]
Stock Issued During Period, Value, New Issues													3,463,178
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues													$ 132,091
Keystone Capital Partners, LLC [Member] | Maximum [Member] | Forecast [Member]
Stock Issued During Period, Value, New Issues	$ 5,147,000
Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						420,000			420,000									420,000
Proceeds from Issuance of Common Stock																		$ 4.20
Stock Issued During Period, Value, New Issues						$ 4,200,000			$ 4,200,000
Proceeds from Issuance of Preferred Stock and Preference Stock																		$ 4,200,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			150,000										1,500
Stock Issued During Period, Value, New Issues			$ 15,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock													$ 150,000
Jubilant [Member]
Stock Issued During Period, Shares, New Issues (in shares)				209,205
Proceeds from Issuance of Common Stock				$ 1
Jubilant [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount				1,000,000
Sale of Stock, Additional Milestone Commitment Amount				$ 19,000,000
Mastiff Group LLC [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount																					$ 25,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)																					$ 0.001
Mastiff Group LLC [Member] | Private Placement [Member] | Forecast [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 5
Mastiff Group LLC [Member] | Private Placement [Member] | Maximum [Member] | Forecast [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 5.75
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)									4,000,000									4,020,588
Proceeds from Issuance of Common Stock									$ 3,400,000									$ 3,400,000
Investor [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount																					$ 25,000
Accounts and Other Receivables [Member]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable											$ 812,000									$ 812,000
Platinum-Montaur Life Sciences LLC Litigation [Member]
Loss Contingency, Damages Sought, Value												$ 1,900,000
CRG Loan Agreement, Ohio Case [Member]
Loss Contingency, Damages Sought, Value															$ 4,300,000
Ohio Court of Common Pleas [Member]
Litigation Settlement, Amount Awarded from Other Party							$ 4,300,000

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Contract with Customer, Payment Term, Minimum (Day)		15 days
Contract with Customer, Payment Term, Maximum (Day)		90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method		$ 0
Revenue from Contract with Customer, Including Assessed Tax	$ 7,000		$ 5,000	$ 31,000	$ 35,000
Contract with Customer, Asset, Impairment Loss	0		$ 0	0	$ 0
Capitalized Contract Cost, Net, Total	0			0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	$ 0			$ 0		$ 0
INDIA
Contract with Customer, Term of Contract (Year)		8 years
CHINA
Contract with Customer, Term of Contract (Year)		10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue from contract with customer	$ 7,000	$ 5,000	$ 31,000	$ 35,000
Royalty [Member]
Revenue from contract with customer	2,047	4,895	26,188	13,985
License [Member]
Revenue from contract with customer	4,726		4,726	9,953
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer	2,047	4,895	26,188	13,985
Diagnostics Segment [Member] | Royalty [Member] | Europe [Member]
Revenue from contract with customer	2,047	4,895	26,188	13,985
Diagnostics Segment [Member] | Expanded Tc99m Tilmanocept License Agreement [Member] | Europe [Member]
Revenue from contract with customer	4,726		4,726
Diagnostics Segment [Member] | NAV4694 Sublicense [Member]
Revenue from contract with customer				9,953
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer	4,726		4,726	9,953
Diagnostics Segment [Member] | Product and Service, Other [Member]
Revenue from contract with customer				$ 11,024

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Total deferred revenue, beginning of period	$ 860,000	$ 1,195,000	$ 700,000	$ 711,024
Revenue deferred related to sublicense			160,000	495,000
Refund of deferred revenue related to sublicense	(160,000)	(495,000)	(160,000)	(495,000)
Revenue recognized from satisfaction of performance obligations				(11,024)
Total deferred revenue, end of period	$ 700,000	$ 700,000	$ 700,000	$ 700,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Expense	$ 63,000	$ 50,000	$ 136,000	$ 178,000
Share-based Payment Arrangement, Expense, Tax Benefit	0	$ 0	0	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 332,000		$ 332,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 219 days

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Outstanding at beginning of period (in shares)	238,470
Outstanding at beginning of period, weighted average exercise price (in dollars per share)	$ 17.38
Outstanding, weighted average remaining contractual life (Year)	8 years 36 days	7 years 73 days
Granted (in shares)	295,000
Granted, weighted average exercise price (in dollars per share)	$ 2.29
Exercised (in shares)
Exercised, weighted average exercise price (in dollars per share)
Canceled and Forfeited (in shares)	(3,000)
Canceled and Forfeited, weighted average exercise price (in dollars per share)	$ 1.06
Expired (in shares)	(500)
Expired, weighted average exercise price (in dollars per share)	$ 30.80
Outstanding at end of period (in shares)	529,970	238,470
Outstanding at end of period, weighted average exercise price (in dollars per share)	$ 9.06	$ 17.38
Outstanding at end of period	$ 314,880
Exercisable at end of period (in shares)	114,870
Exercisable at end of period, weighted average exercise price (in dollars per share)	$ 25.20
Exercisable at end of period, weighted average remaining contractual life (Year)	5 years 109 days
Exercisable at end of period

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Unvested at beginning of period (in shares) | shares	15,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.75
Granted (in shares) | shares	60,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.90
Vested (in shares) | shares	(15,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.75
Forfeited (in shares) | shares
Forfeited, weighted average grant-date fair value (in dollars per share) | $ / shares
Unvested at end of period (in shares) | shares	60,000
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.90

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,106,744	1,490,531
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	60,000	15,000

Note 7 - Accounts Payable, Ac_2

Note 7 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - Director Fees [Member] - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accounts Payable [Member]
Due to Related Parties, Current, Total	$ 65,000	$ 65,000
Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 676,000	$ 925,000

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)	May 18, 2020	Nov. 30, 2019	Nov. 30, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Interest Expense, Debt, Total				$ 0	$ 1,000	$ 5,000	$ 6,000
Notes Payable, Current, Total				366,000		366,000		$ 305,955
Proceeds from Notes Payable, Total						366,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount			$ 393,000
Debt Instrument, Interest Rate, Stated Percentage			5.10%
Debt Instrument, Term (Month)			300 days
Debt Instrument, Periodic Payment, Total			$ 40,000
Interest Expense, Debt, Total					$ 1,000		$ 6,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member]
Debt Instrument, Face Amount		$ 349,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Term (Month)		240 days
Debt Instrument, Periodic Payment, Total		$ 44,000
Interest Expense, Debt, Total				0		5,000
Notes Payable, Current, Total				$ 0		$ 0		$ 306,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 366,000

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended
	Jun. 30, 2017USD ($)	Sep. 30, 2020USD ($)ft²	Sep. 30, 2019USD ($)	Mar. 31, 2019USD ($)ft²	Jun. 30, 2020USD ($)ft²	Sep. 30, 2020USD ($)ft²	Sep. 30, 2019USD ($)
Operating Lease, Expense		$ 49,000	$ 54,000			$ 151,000	$ 176,000
Operating Lease, Payments						$ 246,000	$ 249,000
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		5,000				5,000
Operating Lease, Monthly Base Rent						$ 3,000
Office Space at 560 Sylvan Avenue, Englewood Cliffs, New Jersey [Member]
Area of Real Estate Property (Square Foot) | ft²				2,000
Operating Lease, Monthly Base Rent				$ 3,000
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²					25,000
Operating Lease, Monthly Base Rent					$ 27,000
Lessee, Operating Lease, Renewal Term (Year)					5 years
Operating Lease, Sublease, Monthly Rent Revenue	$ 39,000
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent					$ 300
Office Equipment [Member]
Operating Lease, Monthly Base Rent					$ 100

Note 9 - Leases - Maturity of L

Note 9 - Leases - Maturity of Lease Liabilities (Details)	Sep. 30, 2020USD ($)
2020 (remaining)	$ 92,711
2021	344,552
2022	291,111
2023	19,699
2024	1,355
Total undiscounted operating lease payments	749,428
Less imputed interest	83,279
Present value of operating lease liabilities	$ 666,149

Note 9 - Leases - Balance Sheet

Note 9 - Leases - Balance Sheet Classification (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current lease liabilities	$ 285,913	$ 250,553
Noncurrent lease liabilities	380,236	$ 512,344
Present value of operating lease liabilities	666,149
Other Current Liabilities [Member]
Current lease liabilities	285,913
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 380,236

Note 9 - Leases - Other Informa

Note 9 - Leases - Other Information (Details)	Sep. 30, 2020
Weighted-average remaining lease term for operating leases (in years) (Year)	2 years 36 days
Weighted-average discount rate for operating leases	10.90%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual)

Nov. 27, 2019USD ($)

Apr. 26, 2019

Aug. 14, 2018

Apr. 09, 2018USD ($)

Nov. 02, 2017USD ($)

Mar. 03, 2017USD ($)

Dec. 31, 2019USD ($)shares

Nov. 30, 2018shares

Nov. 30, 2017USD ($)

Jun. 30, 2016USD ($)

Jun. 30, 2019shares

Mar. 31, 2019shares

Sep. 30, 2020USD ($)

Feb. 14, 2020USD ($)

Aug. 31, 2018shares

Stock Issued During Period, Shares, New Issues (in shares) | shares

2,100,000

Stockholders' Equity Attributable to Parent, Ending Balance

$ (1,612,292)

$ 169,877

Market Capitalization, Fair Value

$ 71,200,000

Pro Forma [Member]

Stockholders' Equity Attributable to Parent, Ending Balance

$ 6,000,000

Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares) | shares

8,000,000

17,857

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement (in shares) | shares

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period (Month)

1 year 180 days

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares) | shares

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares) | shares

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5.00%

CRG [Member]

Draws on Letter of Credit

$ 7,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,100,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 4,300,000

Platinum-Montaur Life Sciences LLC Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Maximum [Member] | Before Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

59,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

$ 66,000,000

Note 11 - Equity (Details Textu

Note 11 - Equity (Details Textual) - USD ($)	Jun. 02, 2021	Nov. 05, 2020	Aug. 31, 2020	Aug. 09, 2020	May 06, 2020	Nov. 13, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 30, 2020	Aug. 30, 2020
Stock Issued During Period, Shares, New Issues (in shares)									2,100,000
Proceeds from Issuance of Common Stock								$ 812,000	$ 1,900,000						$ 4,417,560	$ 6,046,915	$ 1,100,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable										$ 5,000,000					$ 5,000,000			$ 5,000,000
Stock Issued During Period, Value, New Issues													$ 5,166,441	$ 50,000
Common Stock, Par or Stated Value Per Share (in dollars per share)									$ 0.001	$ 0.001					$ 0.001		$ 0.001	$ 0.001
Proceeds from Issuance of Preferred Stock and Preference Stock															$ 4,350,000
Preferred Stock, Shares Subscribed but Unissued (in shares)									0	148,500					148,500		0	148,500
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable										$ 14,150,000					$ 14,150,000			$ 14,150,000
Stock Issued During Period, Value, Issued for Services										$ 65,400		$ 4,801
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)															32,651	8,128		8,128
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution															$ 39,834	$ 19,588		$ 20,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)													8,000,000	17,857
Stock Issued During Period, Value, New Issues													$ 8,000	$ 357
Stock Issued During Period, Shares, Issued for Services (in shares)										20,000		3,810
Stock Issued During Period, Value, Issued for Services										$ 20		$ 4
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)											40,844	53,315
Private Placement [Member]
Stock Issued During Period, Value, New Issues											$ 520,030
Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)										461,729	1,911,800	902,162
Stock Issued During Period, Value, New Issues										$ 462	$ 1,912	$ 902
Conversion from Series C Preferred Stock To Common Stock [Member]
Stock Issued During Period, Value, New Issues											$ 700,000
Conversion of Stock, Shares Converted (in shares)															420,000
Conversion of Stock, Shares Issued (in shares)															1,425,076
Conversion from Series C Preferred Stock To Common Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)
Stock Issued During Period, Value, New Issues
Conversion from Series D Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)										1,500					1,500
Conversion of Stock, Shares Issued (in shares)										56,497					56,497
Conversion from Series D Preferred Stock To Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Converted (in shares)						7,000
Conversion of Stock, Shares Issued (in shares)						313,290
Series C Preferred Stock [Member]
Stock Issued During Period, Value, New Issues										$ 3,463,178
Preferred Stock, Deemed Dividend															$ 467,000
Conversion of Stock, Shares Converted (in shares)															420,000
Series C Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)
Stock Issued During Period, Value, New Issues
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues										$ 132,091
Preferred Stock, Deemed Dividend															$ 17,000
Preferred Stock, Shares Subscribed but Unissued (in shares)										700,000					700,000			700,000
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable										$ 14,200,000	$ 14,200,000				$ 14,200,000			$ 14,200,000
Series D Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)
Stock Issued During Period, Value, New Issues
Keystone Capital Partners, LLC [Member] | Forecast [Member] | Maximum [Member]
Stock Issued During Period, Value, New Issues	$ 5,147,000
Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					420,000		420,000								420,000
Proceeds from Issuance of Common Stock															$ 4.20
Stock Issued During Period, Value, New Issues					$ 4,200,000		$ 4,200,000
Convertible Preferred Stock, Discount to Market Rate							10.00%
Convertible Preferred Stock, Maximum Allowed Percentage of Common Stock Outstanding Used in Conversion Shares							19.99%
Proceeds from Issuance of Preferred Stock and Preference Stock															$ 4,200,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			150,000							1,500
Stock Issued During Period, Value, New Issues			$ 15,000,000
Convertible Preferred Stock, Discount to Market Rate			10.00%
Convertible Preferred Stock, Maximum Allowed Percentage of Common Stock Outstanding Used in Conversion Shares			19.99%
Preferred Stock, Deemed Dividend										$ 17,000
Stock Issued During Period, Value, Other			$ 15
Proceeds from Issuance of Preferred Stock and Preference Stock										$ 150,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)						7,000
Proceeds from Issuance of Preferred Stock and Preference Stock						$ 700,000
Jubilant [Member]
Stock Issued During Period, Shares, New Issues (in shares)				209,205
Proceeds from Issuance of Common Stock				$ 1
Jubilant [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount				$ 1,000,000
Mastiff Group LLC [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount																			$ 25,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)																			$ 0.001
Mastiff Group LLC [Member] | Private Placement [Member] | Forecast [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 5
Mastiff Group LLC [Member] | Private Placement [Member] | Forecast [Member] | Maximum [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 5.75
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)							4,000,000								4,020,588
Proceeds from Issuance of Common Stock							$ 3,400,000								$ 3,400,000
Preferred Stock, Shares Subscribed but Unissued (in shares)										700,000					700,000			700,000
Investor [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount																			$ 25,000
Other Liabilities, Current, Total										$ 25,000					$ 25,000			$ 25,000
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)															94,159
Stock Issued During Period, Value, Issued for Services															$ 172,000
Prepaid Expenses and Other Current Assets [Member]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable									$ 812,000								$ 812,000

Note 12 - Stock Warrants (Detai

Note 12 - Stock Warrants (Details Textual) - $ / shares	1 Months Ended	9 Months Ended
	May 31, 2020	Sep. 30, 2020
Class of Warrant or Right, Outstanding (in shares)		991,874
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 18.37
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.20
Warrants and Rights Outstanding, Term (Year)		1 year
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 49.80
Warrants and Rights Outstanding, Term (Year)		14 years 328 days
Series OO Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)	411,000	411,000
Issued Stock Upon Exercise of Warrants, Shares (in shares)	300,595	300,595

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Tax Credit Carryforwards, Alternative Minimum Tax, Percentage Included in Prepaid and Other Current Assets			50.00%
Tax Credit Carryforwards, Alternative Minimum Tax, Percentage Included in Other Noncurrent Assets			50.00%
Unrecognized Tax Benefits, Ending Balance	$ 0		$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	142,200,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	20,100,000
Alternative Minimum Tax [Member]
Tax Credit Carryforward, Amount			$ 621,000
Alternative Minimum Tax [Member] | Prepaid Expenses and Other Current Assets [Member]
Tax Credit Carryforward, Amount		$ 621,000
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credit Carryforward, Amount	$ 8,800,000

Note 14 - Segments (Details Tex

Note 14 - Segments (Details Textual)		3 Months Ended		9 Months Ended
		Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)
Revenues, Total		$ 268,389	$ 236,811	$ 695,762	$ 538,527
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 15,402	34,289	$ 51,501	107,794
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		$ 15,402	$ 34,289	51,501	$ 107,794
Intersegment Eliminations [Member]
Revenues, Total				$ 0
[1]	Depreciation and amortization are reflected in selling, general and administrative expenses ($15,402 and $34,289 for the three-month periods ended September 30, 2020 and 2019, and $51,501 and $107,794 for the nine-month periods ended September 30, 2020 and 2019, respectively).

Note 14 - Segments - Segment In

Note 14 - Segments - Segment Information (Details) - USD ($)		3 Months Ended						9 Months Ended
		Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue from contract with customer		$ 7,000			$ 5,000			$ 31,000	$ 35,000
Grant and other revenue		261,616			231,916			664,848	514,589
Revenues, Total		268,389			236,811			695,762	538,527
Cost of revenue		82			195			1,048	6,559
Research and development expenses		1,377,998			1,801,558			3,659,046	3,612,783
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,773,532			1,485,207			4,894,778	5,001,818
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	15,402			34,289			51,501	107,794
(Loss) income from operations (3)	[3]	(2,898,625)			(3,084,438)			(7,910,611)	(8,190,427)
Other expense (4)	[4]	(713)			10,334			12,045	17,456
Net (loss) income		(2,899,338)	$ (2,325,619)	$ (2,673,608)	(3,074,104)	$ (2,673,179)	$ (2,429,061)	(7,898,566)	(8,176,343)
Total assets, net of depreciation and amortization		5,995,835						5,995,835		$ 4,150,906
International		5,995,835						5,995,835		$ 4,150,906
Capital expenditures		120,810						129,216
Income tax (expense) benefit									(707)
(Loss) income from operations (3)	[3]	(2,898,625)			(3,084,438)			(7,910,611)	(8,190,427)
Other income (4)	[4]	(713)			10,334			12,045	17,456
Net (loss) income		(2,899,338)	$ (2,325,619)	$ (2,673,608)	(3,074,104)	$ (2,673,179)	$ (2,429,061)	(7,898,566)	(8,176,343)
Net loss from continuing operations									(8,173,678)
Loss from discontinued operations, net of tax									(2,665)
UNITED STATES
Total assets, net of depreciation and amortization		5,879,053			4,819,050			5,879,053	4,819,050
International		5,879,053			4,819,050			5,879,053	4,819,050
Non-US [Member]
Total assets, net of depreciation and amortization		116,782			2,606			116,782	2,606
International		116,782			2,606			116,782	2,606
Royalty [Member]
Revenue from contract with customer		2,047			4,895			26,188	13,985
License [Member]
Revenue from contract with customer		4,726						4,726	9,953
Diagnostics Segment [Member]
Grant and other revenue		106,729			77,049			381,103	309,670
Revenues, Total		113,502			81,944			412,017	333,608
Cost of revenue		82			195			1,048	6,559
Research and development expenses		1,251,383			1,678,423			3,402,160	3,194,468
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	4,027						4,027
(Loss) income from operations (3)	[3]	(1,268,605)			(1,596,674)			(2,995,218)	(2,867,419)
Other expense (4)	[4]
Net (loss) income		(1,141,990)			(1,596,746)			(2,995,218)	(2,870,332)
Capital expenditures		120,810						120,810
Income tax (expense) benefit					(72)				(248)
(Loss) income from operations (3)	[3]	(1,268,605)			(1,596,674)			(2,995,218)	(2,867,419)
Other income (4)	[4]
Net (loss) income		(1,141,990)			(1,596,746)			(2,995,218)	(2,870,332)
Net loss from continuing operations									(2,867,667)
Loss from discontinued operations, net of tax									(2,665)
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		1,000			36,811			1,000	36,811
International		1,000			36,811			1,000	36,811
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		116,782			2,606			116,782	2,606
International		116,782			2,606			116,782	2,606
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		2,047			4,895			26,188	13,985
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer		4,726						4,726	9,953
Therapeutics Segment [Member]
Grant and other revenue		154,887			154,867			283,745	204,919
Revenues, Total		154,887			154,867			283,745	204,919
Cost of revenue
Research and development expenses		126,615			123,135			256,886	418,315
Selling, general and administrative expenses, excluding depreciation and amortization	[1]				1,052			(550)	15,828
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
(Loss) income from operations (3)	[3]	28,272			30,680			27,409	(229,224)
Other expense (4)	[4]
Net (loss) income		28,272			30,696			27,409	(229,244)
Capital expenditures
Income tax (expense) benefit					16				(20)
(Loss) income from operations (3)	[3]	28,272			30,680			27,409	(229,224)
Other income (4)	[4]
Net (loss) income		28,272			30,696			27,409	(229,244)
Net loss from continuing operations									(229,244)
Loss from discontinued operations, net of tax
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		38,320			93,860			38,320	93,860
International		38,320			93,860			38,320	93,860
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
International
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer
Corporate Segment [Member]
Grant and other revenue
Revenues, Total
Cost of revenue
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,773,532			1,484,155			4,895,328	4,985,990
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	11,375			34,289			47,474	107,794
(Loss) income from operations (3)	[3]	(1,784,907)			(1,518,444)			(4,942,802)	(5,093,784)
Other expense (4)	[4]	(713)			10,334			12,045	17,456
Net (loss) income		(1,785,620)			(1,508,055)			(4,930,757)	(5,076,767)
Capital expenditures								8,406
Income tax (expense) benefit					55				(439)
(Loss) income from operations (3)	[3]	(1,784,907)			(1,518,444)			(4,942,802)	(5,093,784)
Other income (4)	[4]	(713)			10,334			12,045	17,456
Net (loss) income		(1,785,620)			(1,508,055)			(4,930,757)	(5,076,767)
Net loss from continuing operations									(5,076,767)
Loss from discontinued operations, net of tax
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		5,839,733			4,688,379			5,839,733	4,688,379
International		5,839,733			4,688,379			5,839,733	4,688,379
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
International
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer
Corporate Segment [Member] | License [Member]
Revenue from contract with customer
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Depreciation and amortization are reflected in selling, general and administrative expenses ($15,402 and $34,289 for the three-month periods ended September 30, 2020 and 2019, and $51,501 and $107,794 for the nine-month periods ended September 30, 2020 and 2019, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4]	Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 15 - Supplemental Disclo_2

Note 15 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended		21 Months Ended
	May 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 5,000	$ 6,000
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)					94,159
Stock Issued During Period, Value, Employee Benefit Plan			$ 39,834	$ 19,588	$ 172,000
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)					32,651	8,128	8,128
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution					$ 39,834	$ 19,588	$ 20,000
Conversion from Series C Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)					420,000
Conversion of Stock, Shares Issued (in shares)					1,425,076
Conversion from Series D Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)		1,500			1,500
Conversion of Stock, Shares Issued (in shares)		56,497			56,497
Series C Preferred Stock [Member]
Preferred Stock, Deemed Dividend					$ 467,000
Conversion of Stock, Shares Converted (in shares)					420,000
Series D Preferred Stock [Member]
Preferred Stock, Deemed Dividend					$ 17,000
Series OO Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)	411,000				411,000
Issued Stock Upon Exercise of Warrants, Shares (in shares)	300,595				300,595

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	Aug. 31, 2020	Nov. 13, 2020	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Stock Issued During Period, Shares, New Issues (in shares)			2,100,000
Stock Issued During Period, Value, New Issues					$ 5,166,441	$ 50,000
Proceeds from Issuance of Preferred Stock and Preference Stock							$ 4,350,000
Preferred Stock, Shares Subscribed but Unissued (in shares)			0	148,500			148,500
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable				$ 14,150,000			$ 14,150,000
Conversion from Series D Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				1,500			1,500
Conversion of Stock, Shares Issued (in shares)				56,497			56,497
Conversion from Series D Preferred Stock To Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Converted (in shares)		7,000
Conversion of Stock, Shares Issued (in shares)		313,290
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues				$ 132,091
Preferred Stock, Shares Subscribed but Unissued (in shares)				700,000			700,000
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable				$ 14,200,000			$ 14,200,000		$ 14,200,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	150,000			1,500
Stock Issued During Period, Value, New Issues	$ 15,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 150,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)		7,000
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 700,000